Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Tyrosine kinase inhibitors and signal transduction modulators: Rationale and current status as chemopreventive agents for prostate cancer
Autore:
Bergan, RC; Waggle, DH; Carter, SK; Horak, I; Slichenmyer, W; Meyers, M;
Indirizzi:
Aventis Inc, Parsippany, NJ USA Aventis Inc Parsippany NJ USAAventis Inc, Parsippany, NJ USA Parke Davis, Ann Arbor, MI USA Parke Davis Ann Arbor MI USAParke Davis, Ann Arbor, MI USA Pharmacia, Peapack, NJ USA Pharmacia Peapack NJ USAPharmacia, Peapack, NJ USA Sugen Inc, San Francisco, CA USA Sugen Inc San Francisco CA USASugen Inc, San Francisco, CA USA Prot Technol Inc, St Louis, MO USA Prot Technol Inc St Louis MO USAProt Technol Inc, St Louis, MO USA Northwestern Univ, Robert H Lurie Canc Ctr, Chicago, IL 60611 USA Northwestern Univ Chicago IL USA 60611 ie Canc Ctr, Chicago, IL 60611 USA Northwestern Univ, Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL 60611USA Northwestern Univ Chicago IL USA 60611 ematol Oncol, Chicago, IL 60611USA
Titolo Testata:
UROLOGY
fascicolo: 4A, volume: 57, anno: 2001, supplemento:, S
pagine: 77 - 80
SICI:
0090-4295(200104)57:4A<77:TKIAST>2.0.ZU;2-P
Fonte:
ISI
Lingua:
ENG
Soggetto:
EPIDERMAL GROWTH-FACTOR; FOCAL ADHESION KINASE; MESSENGER-RNA; RECEPTOR; EXPRESSION; PROTEIN; TISSUE; CELLS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
12
Recensione:
Indirizzi per estratti:
Indirizzo: Bergan, RC Olson 8524,710 N Fairbanks, Chicago, IL 60611 USA Olson 8524,710 N Fairbanks Chicago IL USA 60611 , IL 60611 USA
Citazione:
R.C. Bergan et al., "Tyrosine kinase inhibitors and signal transduction modulators: Rationale and current status as chemopreventive agents for prostate cancer", UROLOGY, 57(4A), 2001, pp. 77-80

Abstract

intimately associated with carcinogenesis and regulated by Cell growth anddifferentiation are processes tyrosine kinases and other signaling proteins. Identification of drugs that target signaling molecules is hampered by both the large number of targets and the complex nature of signaling cascades. Optimal development of chemopreventive agents must take into account affinity for the target, pharmacology, and safety profile of the agent, Validated biomarkers will allow the optimal implementation of chemopreventive trials. Directed epidemiologic studies can lead to the identification of lead compounds for chemoprevention, such as genistein. Therefore, agents targeted to pathways and molecules of known biological importance in the prostate hold the promise of clinical efficacy against prostate cancer in a chemopreventive setting. (C) 2001, Elsevier Science Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/11/20 alle ore 15:14:00